Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: Comparison with ultrasonography and contrast-enhanced CT

Annals of Nuclear Medicine

Volumn 23, Issue 10, 2009, Pages 855-861

  Monzawa, Shuichi ^a,b   Adachi, Shuji ^a   Suzuki, Kayo ^a   Hirokaga, Koichi ^a   Takao, Shintaro ^a   Sakuma, Toshiko ^a   Hanioka, Keisuke ^a,b  

^a HYOGO CANCER CENTER   (Japan)

^b Akashi Municipal Hospital   (Japan)

Author keywords

Breast cancer; CT; Lymph node metastasis; PET CT; Ultrasonography

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, MAMMARY;

EID: 72949104910     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-009-0314-9     Document Type: Article

References (35)

1. FW Childberg F Lohe 1996 Basic principles and value of lymphadenectomy in breast carcinoma Chirurg 67 771 778 10.1007/PL00002520
2. HS Cody III 2002 Current surgical management of breast cancer Curr Opin Obstet Gynecol 14 45 52 10.1097/00001703-200202000-00008 11801876 (Pubitemid 34177907)
3. W Kwan J Jackson LM Weir C Dingee G McGregor IA Olivotto 2002 Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life J Clin Oncol 20 4242 4248 10.1200/JCO.2002.09.018 12377968 (Pubitemid 35191027)
4. A Fleissig LJ Fallowfield Cl Langridge L Johnson RG Newcombe JM Dixon, et al. 2006 Post-operative arm morbidity and quality of life: results of the ALMANAC randomized trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer Breast Cancer Res Treat 95 279 293 10.1007/s10549-005-9025-7 16163445
5. C Chao K McMasters 2002 The current status of sentinel lymph node biopsy for breast cancer Adv Surg 36 167 192 12465551
6. GH Lyman AE Giuliano MR Somerfield AB Benson 3rd DC Bodurka HJ Burstein, et al. 2005 American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer J Clin Oncol 23 7703 7720 10.1200/JCO.2005.08.001 16157938 (Pubitemid 46291835)
7. CE Cox S Pendas JM Cox E Joseph AR Shons T Yeatman, et al. 1998 Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer Ann Surg 227 645 651 10.1097/00000658-199805000-00005 1:STN:280:DyaK1c3ms1KqsQ%3D%3D 9605656 (Pubitemid 28530914)
8. BJ O'Hea ADK Hill AM El-Shirbany SD Yeh PP Rosen DG Coit, et al. 1998 Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center J Am Coll Surg 186 423 427 10.1016/S1072-7515(98) 00060-X 9544956 (Pubitemid 28169364)
9. D Krag D Weaver T Ashikaga F Moffat VS Klimberg C Shriver, et al. 1998 The sentinel node in breast cancer: a multicenter validation study N Engl J Med 339 941 946 10.1056/NEJM199810013391401 1:STN:280:DyaK1cvhvVKntg%3D%3D 9753708 (Pubitemid 28455095)
10. DE March RJ Wechsler AB Kurtz AL Rosenberg L Needleman 1991 CT-pathologic correlation of axillary lymph nodes in breast carcinoma J Comput Assist Tomogr 15 440 444 10.1097/00004728-199105000-00017 1:STN:280:DyaK3M3isFaquw%3D%3D 2026806
11. A Lernevall 2000 Imaging of axillary lymph nodes Acta Oncol 39 277 281 10.1080/028418600750013014 1:STN:280:DC%2BD3cvlsVCrug%3D%3D 10987221
12. S Alvarez E Añorbe P Alcorta F López I Alonso J Cortés 2006 Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review AJR Am J Roentgenol 186 1342 1348 10.2214/AJR.05.0936 16632729 (Pubitemid 46112571)
13. LP Adler JP Crowe NK al-Kaisi JL Sunshine 1993 Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-d-glucose PET Radiology 187 743 750 1:STN:280:DyaK3s3mvV2jsg%3D%3D 8497624
14. CI Utech CS Young PF Winter 1996 Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry Eur J Nucl Med 23 1588 1593 10.1007/BF01249621 1:STN:280:DyaK2s%2FotlKlug%3D%3D 8929312 (Pubitemid 27023055)
15. N Avril J Dose F Jänicke S Ziegler W Römer W Weber, et al. 1996 Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy- d-glucose J Natl Cancer Inst 88 1204 1209 10.1093/jnci/88.17.1204 1:STN:280:DyaK28znsVegug%3D%3D 8780629
16. IC Smith KN Ogston P Whitford FW Smith P Sharp M Norton, et al. 1998 Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose Ann Surg 228 220 227 10.1097/00000658-199808000-00012 1:STN:280:DyaK1czns1CisQ%3D%3D 9712568 (Pubitemid 30191718)
17. M Greco F Crippa R Agresti E Seregni A Gerali R Giovanazzi, et al. 2001 Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-d-glucose- positron emission tomography: clinical evaluation and alternative management J Natl Cancer Inst 93 630 635 10.1093/jnci/93.8.630 1:STN:280: DC%2BD3Mzht1KntA%3D%3D 11309439
18. H Schirrmeister T Kühn A Guhlmann C Santjohanser T Hörster K Nüssle, et al. 2001 Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nucl Med 28 351 358 10.1007/s002590000448 1:CAS:528: DC%2BD3MXitFeiu7o%3D 11315604
19. JJ van der Hoeven OS Hoekstra EF Comans R Pijpers RP Boom D van Geldere, et al. 2002 Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer Ann Surg 236 619 624 10.1097/00000658-200211000-00012 12409668 (Pubitemid 35246894)
20. E Barranger D Grahek M Antoine F Montravers JN Talbot S Uzan 2003 Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer Ann Surg Oncol 10 622 627 10.1245/ASO.2003.12.019 12839846 (Pubitemid 40486893)
21. MK Fehr R Hornung Z Varga D Burger T Hess U Haller, et al. 2004 Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy Breast J 10 89 93 10.1111/j.1075-122X.2004.21455. x 15009033 (Pubitemid 38375027)
22. L Weir D Worsley V Bernstein 2005 The value of FDG positron emission tomography in the management of patients with breast cancer Breast J 11 204 209 10.1111/j.1075-122X.2005.21625.x 15871707 (Pubitemid 40664065)
23. RL Wahl BA Siegel RE Coleman CG Gatsonis PET Study Group 2004 Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group J Clin Oncol 22 277 285 10.1200/JCO.2004.04.148 14722036 (Pubitemid 41095092)
24. DW Townsend JP Carney JT Yap NC Hall 2004 PET/CT today and tomorrow J Nucl Med 45 4S 13S 14736831
25. SK Boolbol JV Fey PI Borgen AS Heerdt LL Montgomery M Paglia, et al. 2001 Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma Ann Surg Oncol 8 20 24 10.1007/s10434-001-0020-x 1:STN:280:DC%2BD3M7lsFeltg%3D%3D 11206219
26. K Suga Y Yuan M Okada N Matsunaga A Tangoku S Yamamoto, et al. 2004 Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience Radiology 230 543 552 10.1148/radiol.2302021380 14699178 (Pubitemid 38133820)
27. J Verbanck I Vandewiele H De Winter J Tytgat F Van Aelst W Tanghe 1997 Value of axillary ultrasonography and sonographically guided needle biopsy of axillary nodes: a prospective study in 144 consecutive patients J Clin Ultrasound 25 53 56 10.1002/(SICI)1097-0096(199702)25:2<53::AID-JCU1>3.0. CO;2-I 1:STN:280:DyaK2s7ns1Wiug%3D%3D 9023691 (Pubitemid 27058463)
28. WT Yang A Ahuja A Tang M Suen W King C Metreweli 1996 High resolution sonographic detection of axillary lymph node metastases in breast cancer J Ultrasound Med 16 241 246
29. Miyauchi M, Yamamoto N, Imanaka N, Matsumoto M. Computed tomography for preoperative evaluation of axillary nodal status in breast cancer. Breast Cancer. 1999;6:243-8.
30. NC Hodgson KY Gulenchyn 2008 Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 26 712 720 10.1200/JCO.2007.13.8412 18258978 (Pubitemid 351264383)
31. PJ Lovrics V Chen G Coates SD Cornacchi CH Goldsmith C Law 2004 A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer Ann Surg Oncol 11 846 853 10.1245/ASO.2004.11.033 15313737 (Pubitemid 40568812)
32. F Crippa R Agresti E Seregni M Greco C Pascali A Bogni, et al. 1998 Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer J Nucl Med 39 4 8 1:STN:280:DyaK1c7gtl2ltA%3D%3D 9443729
33. U Veronesi C De Cicco VE Galimberti JR Fernandez N Rotmensz G Viale, et al. 2007 A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases Ann Oncol 18 473 478 10.1093/annonc/mdl425 1:STN:280:DC%2BD2szlt1ajtg%3D%3D 17164229 (Pubitemid 46359625)
34. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer J Clin Oncol 19 3516 3523 1:STN:280:DC%2BD3MvjtlOmtQ%3D%3D 11481358
35. K Kitajima K Murakami E Yamasaki Y Domeki M Tsubaki M Sunagawa, et al. 2009 Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast- enhanced CT and enhanced CT Eur J Nucl Med Mol Imaging 36 1388 1396 10.1007/s00259-009-1081-5 19370346